6533b860fe1ef96bd12c3b49
RESEARCH PRODUCT
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis
Maria GuarinoLuca ViganòFrancesca Romana PonzianiEdoardo Giovanni GianniniQuirino LaiFilomena MoriscoAlessandro VitaleFrancesco Paolo RussoUmberto CilloPatrizia BurraClaudia MescoliMartina GambatoAnna SessaGiuseppe CabibboMauro ViganòGiovanni GalatiErica VillaMassimo IavaroneGiuseppina BrancaccioMaria RendinaLuigi G. LupoFrancesco LositoFabio FucilliMarcello PersicoRoberta D'ambrosioAngelo SangiovanniAlessandro CucchettiFranco TrevisaniRenzulli MatteoLuca MieleAntonio GriecoGian Lodovico RapacciniMaurizio PompiliAntonio GasbarriniGiovanni Battisa Levi SandriFabio MelandroMassimo RossiIlaria LenciTommaso Maria ManziaRaffaella TortoraGiovan Giuseppe Di CostanzoRodolfo SaccoDavide GhinolfiErion RrekaPaola CarraiNatalia SimonettiCarlo SpositoSherrie BhooriStefano Di SandroFrancesco Giuseppe FoschiAndrea Casadei‐gardiniDaniele NicoliniSusanna MazzocatoAlba KostandiniPaola VioliUmberto BaccaraniRiccardo PravisaniValter Vincenzisubject
OncologyLiver CirrhosisCirrhosisSustained Virologic ResponseDAA; HCC; HCV; Recurrencemedicine.disease_causelaw.invention0302 clinical medicineRandomized controlled triallawDAA; HCC; HCV; Recurrence; Antiviral Agents; Carcinoma Hepatocellular; Disease Progression; Hepatitis C Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence Local; Neoplasm Staging; Risk Assessment; Sustained Virologic ResponseRecurrenceHCCChronicLiver NeoplasmsGastroenterologyhepatocellular carcinomaHepatitis CLocalDAA; HCC; HCV; Recurrence; Hepatology; Gastroenterology030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyRisk assessmentDirect actingRisk analysismedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusAntiviral AgentsRisk AssessmentDAA HCC HCV Recurrence03 medical and health sciencesInternal medicinemedicineHumansAntiviral treatmentDAANeoplasm StagingHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseaseSettore MED/18 - Chirurgia GeneraleNeoplasm RecurrenceNeoplasm Recurrence Localbusinessdescription
Although studies suggest decreased incident hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are conflicting regarding risk and aggressiveness of recurrence in patients who have a history of treated HCC. This review analyses data available in literature in order to elucidate the impact of DAAs on the risk of HCC recurrence after successful treatment of the tumor. Overall 24 papers were identified. The available data cannot be considered definitive, but the initial alarmist data indicating an increased risk of recurrence have not been confirmed by most subsequent studies. The suggested aggressive pattern (rapid growth and vascular invasion) of tumor recurrence after DAAs still remains to be confirmed. Several limitations of the available studies were highlighted, and should drive future researches. The time-to-recurrence should be computed since the last HCC treatment and results stratified for cirrhosis and sustained viral response. Any comparison with historical series is of limited interest because of a number of biases affecting these studies and differences between enrolled patients. Prospective intention-to-treat analyses will be probably the best contribution to drive clinical practice, provided that a randomized trial can be difficult to design.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 |